Results 171 to 180 of about 414,079 (344)

A Case of Pembrolizumab‐Induced Pityriasis Lichenoides‐Like Eruption Treated Successfully With Dupilumab

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Immune‐checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long‐standing cutaneous immune‐related adverse events (cirAEs). We report a case of refractory pembrolizumab‐induced pityriasis lichenoides (PL)‐like eruption successfully treated with dupilumab, leading to rapid and sustained remission ...
Evangelos Christou   +2 more
wiley   +1 more source

Successful Use of Bimekizumab in Refractory Acute Generalised Exanthematous Pustulosis Triggered by Amoxicillin‐Clavulanate

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Acute generalised exanthematous pustulosis (AGEP) is a rare, acute neutrophilic dermatosis most commonly triggered by drugs, which typically resolves within 2 weeks following withdrawal of the causative agent. Topical and systemic corticosteroids remain the standard treatment.
Alexandra Junge   +5 more
wiley   +1 more source

Editorial: Volcanic Islands—A Challenge for Volcanology

open access: yesFrontiers in Earth Science, 2022
Alessandro Bonforte   +3 more
doaj   +1 more source

Granulomatous Panniculitis in a Patient Treated With Cemiplimab: Case Report and Literature Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of advanced malignancies by enhancing antitumor immunity, but they may also trigger a broad spectrum of immune‐related adverse events (irAEs) involving multiple organs.
B. Lada‐Colunga   +6 more
wiley   +1 more source

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni   +6 more
wiley   +1 more source

Assessment of Treatment Response in Patients With Scleromyxedema by the Double Modified Rodnan Skin Score

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Scleromyxedema (SMX) is a cutaneous mucinosis characterised by an abnormal accumulation of mucin in the skin and limited treatment options. Assessment of therapy response during treatment is challenging. Objectives Patients with SMX receiving high‐dose intravenous IVIg therapy were included to assess validity of the double modified ...
Julia K. Winkler, Alexander H. Enk
wiley   +1 more source

Immunotherapy‐Related Cutaneous Toxicities in Melanoma: A Dermoscopic Perspective

open access: yesJEADV Clinical Practice, EarlyView.
Dermoscopy serves as a valuable tool in the everyday dermatological and oncological practice for melanoma patients, allowing for the prompt identification of immune‐related cutaneous toxicities and guiding clinicians toward appropriate therapeutic decisions.
Grażyna Kamińska‐Winciorek   +3 more
wiley   +1 more source

Complex eruption processes and deposits of basaltic fissures: insights from the ~37 ka Budj Bim volcanic complex, Southeastern Australia. [PDF]

open access: yesBull Volcanol
Kavanagh JL   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy